OncoMatch/Clinical Trials/NCT07027514
A Study of Tolododekin Alfa (ANK-101) in Combination With an Anti-PD-1/PD-L1 Antibody in Participants With Advanced Non-Small Cell Lung Cancer
Is NCT07027514 recruiting? Yes, currently enrolling (Sep 2026). This Phase 1 trial studies multiple treatments including tolododekin alfa and Cetrelimab for non small cell lung cancer.
Treatment: tolododekin alfa · Cetrelimab — A study of tolododekin alfa (also known as ANK-101) administered in combination with an anti-programmed cell death protein 1 (PD-1)/programmed cell death ligand 1 (PD-L1) antibody in participants with advanced or metastatic non-small cell lung cancer (NSCLC). Cohort A will enroll participants who have progressed on prior standard of care treatment with an anti-PD-1/PD-L1 antibody and a platinum-based chemotherapy regimen. Cohort B will enroll participants who are treatment-naïve for locally advanced or metastatic NSCLC.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Non-Small Cell Lung Carcinoma
Biomarker criteria
Excluded: ALK mutation
Excluded: EGFR mutation
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: immune checkpoint inhibitor
Cohort B only: Prior therapy with an immune checkpoint inhibitor.
Cannot have received: recombinant interleukin-12
Have had prior treatment with recombinant interleukin-12 (IL-12)
Lab requirements
Cardiac function
baseline electrocardiogram (ECG) without evidence of acute ischemia or prolonged QT interval; exclusion for congestive heart failure, active coronary artery disease, unevaluated new onset angina, unstable angina, or clinically significant cardiac arrhythmias
Have baseline electrocardiogram (ECG) without evidence of acute ischemia or prolonged QT interval; Have congestive heart failure, active coronary artery disease, unevaluated new onset angina, unstable angina, or clinically significant cardiac arrhythmias [excluded]
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- University of Miami · Coral Gables, Florida
- Mayo Clinic · Jacksonville, Florida
- OSF Healthcare System; Saint Francis Medical Center · Peoria, Illinois
- Community Health Network · Indianapolis, Indiana
- Barbara Ann Karmanos Cancer Hospital · Detroit, Michigan
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT07027514 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior immune checkpoint inhibitor, recombinant interleukin-12 disqualifies patients from enrollment.
Are patients with ALK alterations eligible?
No. ALK mutation is an exclusion criterion.
Are patients with EGFR alterations eligible?
No. EGFR mutation is an exclusion criterion.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages